Unicycive Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 12, 2025, UNCY reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.56 USD, resulting in a 41.88% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.31% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Unicycive Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Unicycive Therapeutics, Inc. Common Stock reported EPS of -$0.33, beating estimates by 41.88%, and revenue of $0.00, 0% as expectations.
How did the market react to Unicycive Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 7.31%, changed from $4.79 before the earnings release to $5.14 the day after.
When is Unicycive Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Unicycive Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Unicycive Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.